UBS Cuts Carlyle Target to $65 Amid Regulatory Tightening and PE‑Market Headwinds
UBS cuts Carlyle’s target price to $65 amid tighter regulation and weaker PE deal flow, highlighting risks and a cautious outlook for the private‑equity firm.
4 minutes to read









